Original Article

Abnormal Promoter Methylation of Nucleotide-Binding Oligomerization Domain Containing 2 (NOD2) Gene in the Pathogenesis of Crohn’s Disease

Abstract

Background: Changes in the expression of nucleotide-binding oligomerization domain containing 2 (NOD2) play an important role in the pathogenesis of a variety of autoimmune diseases including inflammatory bowel diseases (IBDs). Epigenetic modifications, including DNA methylation, are considered an important mechanism in the suppression of gene activity. In this study, we investigated the relationship between DNA methylation patterns of the promoter region of the NOD2 gene and the pathogenesis of Crohn’s disease (CD).

Methods: Colonic mucosa samples were obtained from 15 Iranian patients with IBD and 15 age- and sex-matched healthy controls with no history of autoimmune disease. After the bisulfite conversion of genomic DNA, the DNA methylation status of three CpG sites in the promoter region of the NOD2 gene was determined by the real-time quantitative multiplex methylation-specific PCR (QM-MSP) assay.

Results: Using this approach, we identified that IBD patients showed a decreased level of methylation of the NOD2 promoter in the colonic mucosa than did the healthy controls. (Unmethylated DNA in Crohn's disease vs. healthy controls; 0.128±0.093 vs. 0.025±0.016, P<0.000).

Conclusion: According to our findings, promoter hypomethylation of the NOD2 gene in the colonic mucosa might contribute to the development and severity of CD. Furthermore, aberrant DNA methylation levels are expected to serve as a clinically useful risk marker.

1. Barnett M, Bermingham E, McNabb W, Bassett S, Armstrong K, Rounce J, et al. Investigating micronutrients and epigenetic mechanisms in relation to inflammatory bowel disease. Mutat Res. 2010;690(1-2):71-80.
2. Kim SW, Kim ES, Moon CM, Kim TI, Kim WHCheon JH. Abnormal genetic and epigenetic changes in signal transducer and activator of transcription 4 in the pathogenesis of inflammatory bowel diseases. Dig Dis Sci. 2012;57(10):2600-7.
3. Cheon J, Kim S, Jeon S, Kim TKim W. Associations of genetic polymorphisms and epigenetic changes in interleukin 17A and interleukin 23 receptor with inflammatory bowel disease.: P‐029. Inflamm Bowel Dis. 2011;17:S21.
4. Nielsen HMTost J. Epigenetic changes in inflammatory and autoimmune diseases. Epigenetics: Development and Disease: Springer; 2013. p. 455-78.
5. Bäckdahl L, Bushell ABeck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. The international journal of biochemistry & cell biology. 2009;41(1):176-84.
6. Petronis APetroniene R. Epigenetics of inflammatory bowel disease. Gut. 2000;47(2):302-6.
7. Lin Z, Hegarty JP, Yu W, Cappel JA, Chen X, Faber PW, et al. Identification of disease-associated DNA methylation in B cells from Crohn's disease and ulcerative colitis patients. Dig Dis Sci. 2012;57(12):3145-53.
8. Cooke J, Zhang H, Greger L, Silva AL, Massey D, Dawson C, et al. Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(11):2128-37.
9. Lin Z, Hegarty JP, Cappel JA, Yu W, Chen X, Faber P, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2011;80(1):59-67.
10. Hartnett LEgan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 2012;33(4):723-31.
11. Gonsky R, Deem RL, Landers CJ, Derkowski CA, Berel D, McGovern DP, et al. Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens. Inflamm Bowel Dis. 2011;17(1):171-8.
12. Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol. 2008;14(3):338-47.
13. Strober WWatanabe T. NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease. Mucosal Immunol. 2011;4(5):484-95.
14. Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, et al. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut. 2003;52(6):840-6.
15. Lo PK, Watanabe H, Cheng PC, Teo WW, Liang X, Argani P, et al. MethySYBR, a novel quantitative PCR assay for the dual analysis of DNA methylation and CpG methylation density. J Mol Diagn. 2009;11(5):400-14.
16. Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, de Haar Cvan der Woude CJ. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis. 2012;33(10):1889-96.
17. Schmittgen TDLivak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.
18. Husseiny MI, Kuroda A, Kaye AN, Nair I, Kandeel FFerreri K. Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes. PLoS One. 2012;7(10):e47942.
19. Saito S, Kato J, Hiraoka S, Horii J, Suzuki H, Higashi R, et al. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis. 2011;17(9):1955-65.
20. Scarpa MStylianou E. Epigenetics: Concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis. 2012;18(10):1982-96.
21. Kellermayer R, Balasa A, Zhang W, Lee S, Mirza S, Chakravarty A, et al. Epigenetic maturation in colonic mucosa continues beyond infancy in mice. Hum Mol Genet. 2010;19(11):2168-76.
22. Wilson AS, Power BEMolloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta. 2007;1775(1):138-62.
23. Lee JCParkes M. Genome-wide association studies and Crohn's disease. Brief Funct Genomics. 2011;10(2):71-6.
24. Yamada Y, Nishida T, Horibe H, Oguri M, Kato KSawabe M. Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation. Int J Mol Med. 2014;33(5):1355-63.
Files
IssueVol 6, No 3 (2023) QRcode
SectionOriginal Article
DOI https://doi.org/10.18502/igj.v6i3.16575
Keywords
NOD2 Inflammatory Bowel Disease Crohn’s Disease DNA Methylation
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sanati G, Noruzinia M, Jafari D, Ahmadvand M, Teimourian S, Ebrahimi Daryani N, Hanaei S, Rezaei N. Abnormal Promoter Methylation of Nucleotide-Binding Oligomerization Domain Containing 2 (NOD2) Gene in the Pathogenesis of Crohn’s Disease. Immunol Genet J. 2023;6(3):108-114.